Funda Meric–bernstam

Funda Meric–bernstam's AcademicInfluence.com Rankings

Philosophy

#4188

World Rank

#6609

Historical Rank

Logic

#1704

World Rank

#2529

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Funda Meric–bernstam's Degrees

Doctorate Medicine Hacettepe University

Why Is Funda Meric–bernstam Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Funda Meric–bernstam's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Immune Landscape of Cancer (2018) (2766)
Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children (2018) (1570)
Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing (2014) (902)
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. (2009) (851)
PD-L1 Expression in Triple-Negative Breast Cancer (2014) (833)
Targeting the PI3K pathway in cancer: are we making headway? (2018) (657)
Targeting the mTOR signaling network for cancer therapy. (2009) (645)
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. (2008) (631)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes (2013) (576)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer (2011) (520)
Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
HER kinase inhibition in patients with HER2- and HER3-mutant cancers (2018) (500)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer (2014) (490)
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
A pan-cancer proteomic perspective on The Cancer Genome Atlas (2014) (437)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020) (432)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. (2020) (430)
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. (2009) (426)
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. (2011) (384)
Punctuated Copy Number Evolution and Clonal Stasis in Triple-Negative Breast Cancer (2016) (375)
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. (2015) (342)
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications (2014) (336)
Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells (2004) (316)
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients (2017) (316)
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. (2018) (297)
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. (2004) (295)
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. (2005) (295)
Determinants of Rapamycin Sensitivity in Breast Cancer Cells (2004) (294)
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. (2009) (288)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients (2009) (282)
Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing (2018) (273)
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes (2009) (271)
Role for Intraoperative Margin Assessment in Patients Undergoing Breast-Conserving Surgery (2007) (262)
Instruments to assess the quality of health information on the World Wide Web: what can our patients actually use? (2005) (257)
Biliary cancer: Utility of next‐generation sequencing for clinical management (2016) (254)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. (2019) (253)
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. (2007) (249)
Effect of Primary Tumor Extirpation in Breast Cancer Patients Who Present With Stage IV Disease and an Intact Primary Tumor (2006) (247)
Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy (2006) (244)
Nanomedicine in cancer therapy: Innovative trends and prospects (2011) (238)
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers (2010) (224)
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer (2011) (222)
Accuracy and self correction of information received from an internet breast cancer list: content analysis (2006) (212)
Metformin: A Therapeutic Opportunity in Breast Cancer (2010) (209)
Oncogenic LncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression (2019) (204)
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors (2012) (198)
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2‐positive breast cancer (2010) (192)
Rak functions as a tumor suppressor by regulating PTEN protein stability and function. (2009) (191)
Targeting TRK family proteins in cancer (2017) (189)
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes (2014) (188)
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes (2017) (186)
Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq (2013) (180)
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. (2018) (178)
The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. (2006) (176)
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. (2018) (173)
Which threshold for ER positivity? a retrospective study based on 9639 patients. (2014) (171)
Trends in and Outcomes from Sentinel Lymph Node Biopsy (SLNB) Alone vs. SLNB with Axillary Lymph Node Dissection for Node-Positive Breast Cancer Patients: Experience from the SEER Database (2010) (171)
Systematic Functional Annotation of Somatic Mutations in Cancer. (2018) (169)
A decision support framework for genomically informed investigational cancer therapy. (2015) (168)
Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancer (2012) (167)
Patient-derived xenograft (PDX) models in basic and translational breast cancer research (2016) (166)
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (2021) (164)
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. (2011) (163)
Metastases to the breast from nonbreast solid neoplasms (2007) (163)
American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns (2012) (162)
Mammalian target of rapamycin. (2004) (161)
Feasibility and Accuracy of Sentinel Lymph Node Biopsy After Preoperative Chemotherapy in Breast Cancer Patients With Documented Axillary Metastases (2007) (161)
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. (2016) (160)
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. (2006) (160)
Targeting the PI3-kinase/Akt/mTOR signaling pathway. (2013) (159)
The impact of pregnancy on breast cancer outcomes in women ≤35 years (2009) (158)
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer (2012) (158)
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer (2013) (154)
Clinical and molecular characterization of early‐onset colorectal cancer (2019) (151)
Breast conservation after neoadjuvant chemotherapy (2005) (149)
Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases After a Positive Sentinel Node Biopsy (2006) (144)
Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer (2006) (144)
Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy (2010) (144)
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer (2018) (143)
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. (2013) (142)
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. (2007) (142)
Low locoregional failure rates in selected breast cancer patients with tumor‐positive sentinel lymph nodes who do not undergo completion axillary dissection (2007) (132)
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. (2010) (132)
Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. (2010) (131)
The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer (2004) (130)
Overcoming implementation challenges of personalized cancer therapy (2012) (130)
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. (2016) (129)
Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. (2003) (128)
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab (2017) (127)
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience (2018) (125)
Incorporation of Sentinel Lymph Node Metastasis Size Into a Nomogram Predicting Nonsentinel Lymph Node Involvement in Breast Cancer Patients With a Positive Sentinel Lymph Node (2012) (122)
Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial (2011) (122)
Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy (2006) (121)
Trends for inflammatory breast cancer: is survival improving? (2007) (120)
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. (2017) (119)
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. (2010) (119)
Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma (2014) (118)
Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. (2005) (115)
Enhancing anti-tumour efficacy with immunotherapy combinations (2020) (115)
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials (2017) (114)
Prospective Evaluation of the Nipple–Areola Complex Sparing Mastectomy for Risk Reduction and for Early-Stage Breast Cancer (2012) (113)
ALK: a tyrosine kinase target for cancer therapy (2017) (113)
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. (2019) (112)
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation (2019) (111)
A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer (2011) (110)
Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers (2017) (109)
State-of-the-Art Strategies for Targeting RET-Dependent Cancers. (2020) (108)
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? (2015) (107)
Building a personalized medicine infrastructure at a major cancer center. (2013) (107)
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. (2012) (106)
Improving local control with breast‐conserving therapy (2005) (105)
Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. (2012) (105)
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set (2016) (105)
cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes (2012) (105)
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design (2020) (103)
Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer (2014) (102)
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. (2009) (102)
CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features (2013) (102)
A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer (2009) (101)
Efficacy of Quality Criteria to Identify Potentially Harmful Information: A Cross-sectional Survey of Complementary and Alternative Medicine Web Sites (2004) (100)
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer (2011) (99)
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. (2016) (99)
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations (2011) (99)
Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation (2011) (98)
Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. (2011) (98)
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations (2020) (98)
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling (2008) (97)
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. (2015) (96)
Commonly cited website quality criteria are not effective at identifying inaccurate online information about breast cancer (2008) (96)
Clinical actionability enhanced through deep targeted sequencing of solid tumors. (2015) (96)
Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis (2005) (94)
Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer (2017) (93)
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. (2011) (93)
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. (2018) (93)
Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy (2006) (91)
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. (2021) (91)
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy (2012) (90)
Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor (2009) (90)
Incidence and Prevention of Venous Thromboembolism in Patients Undergoing Breast Cancer Surgery and Treated According to Clinical Pathways (2006) (90)
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. (2019) (89)
Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast-Conserving Therapy (2013) (88)
Immediate Breast Reconstruction can Impact Postmastectomy Irradiation (2005) (87)
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies (2015) (87)
Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. (2007) (87)
Breast Tumors Maintain a Reservoir of Subclonal Diversity During Expansion (2021) (86)
Contralateral prophylactic mastectomy (2004) (85)
Targeting AKT for cancer therapy (2019) (85)
Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. (2006) (84)
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept (2018) (83)
PD-L 1 Expression in Triple-Negative Breast Cancer (2014) (83)
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer (2009) (82)
Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification (2018) (82)
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer (2015) (82)
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2019) (81)
Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma (2004) (80)
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. (2011) (79)
Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. (2013) (77)
Earlier age of onset of BRCA mutation‐related cancers in subsequent generations (2012) (77)
Selective use of sentinel lymph node surgery during prophylactic mastectomy (2006) (77)
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. (2009) (76)
How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? (2008) (76)
Phase 2 study of pembrolizumab in patients with advanced rare cancers (2020) (76)
Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. (2009) (75)
Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. (2011) (75)
Biology, Treatment, and Outcome in Very Young and Older Women with DCIS (2012) (75)
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. (2014) (74)
Paget’s Disease of the Breast: There Is a Role for Breast-Conserving Therapy (2005) (74)
Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. (2008) (74)
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations (2019) (74)
High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients (2012) (74)
Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy (2010) (74)
Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. (2005) (74)
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System (2016) (73)
Chest Wall Recurrence After Mastectomy Does Not Always Portend a Dismal Outcome (2003) (72)
Local, regional, and systemic recurrence rates in patients undergoing skin‐sparing mastectomy compared with conventional mastectomy (2011) (72)
Clinical outcome of patients with lymph node‐negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry (2005) (72)
Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors (2015) (71)
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma (2019) (70)
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer (2017) (69)
Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic (2014) (69)
Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women <or=55 years. (2006) (69)
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. (2013) (69)
Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. (2018) (68)
Hepatocellular carcinoma: Where there is unmet need (2015) (67)
Breast cancer multifocality and multicentricity and locoregional recurrence. (2013) (67)
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors (2020) (66)
A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients (2010) (66)
Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer (2012) (66)
A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes (2011) (65)
Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. (2017) (65)
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer (2012) (65)
Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer (2010) (65)
Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. (2009) (65)
Primary Tumor Extirpation in Breast Cancer Patients Who Present with Stage IV Disease is Associated with Improved Survival (2013) (64)
Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers (2012) (64)
PurityEst: estimating purity of human tumor samples using next-generation sequencing data (2012) (64)
Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. (2013) (64)
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas (2017) (63)
RET fusion as a novel driver of medullary thyroid carcinoma. (2015) (63)
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases (2008) (63)
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms (2014) (63)
Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial (2013) (63)
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease (2014) (63)
Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. (2013) (63)
Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. (2018) (63)
Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. (2006) (63)
Rapamycin regulates the phosphorylation of rictor. (2007) (62)
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. (2019) (62)
Association between clinical characteristics and risk‐reduction interventions in women who underwent BRCA1 and BRCA2 testing (2006) (62)
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. (2018) (62)
HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. (2016) (61)
First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. (2019) (60)
Prognostic significance of HER‐2 status in women with inflammatory breast cancer (2008) (60)
Promoter polymorphism (−786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non‐Hispanic white women age younger than 55 years (2006) (60)
Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. (2020) (60)
TransVar: a multilevel variant annotator for precision genomics (2015) (59)
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast (2011) (59)
FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors (2014) (58)
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study (2019) (57)
Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer (2017) (57)
Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy (2009) (56)
Evaluation of the MD Anderson Prognostic Index for Local-Regional Recurrence After Breast Conserving Therapy in Patients Receiving Neoadjuvant Chemotherapy (2012) (54)
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma (2018) (54)
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies (2017) (54)
Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. (2014) (53)
FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. (2020) (53)
Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway. (2017) (53)
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. (2015) (52)
Decreased TGFβ signaling and increased COX2 expression in high risk women with increased mammographic breast density (2009) (52)
The safety of breast‐conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy (2006) (51)
The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. (2015) (51)
Usability of quality measures for online health information: Can commonly used technical quality criteria be reliably assessed? (2005) (51)
Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy Can Predict Patient Prognosis and Facilitate Treatment Planning (2011) (51)
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors (2014) (50)
Multifocality and multicentricity in breast cancer and survival outcomes. (2012) (50)
Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected. (2006) (50)
Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. (2014) (50)
Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ (2004) (49)
Histologic changes associated with false‐negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node‐positive breast cancer before treatment (2010) (49)
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study (2021) (49)
Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. (2015) (49)
Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. (2007) (48)
Lymphatic Drainage Patterns on Early Versus Delayed Breast Lymphoscintigraphy Performed after Injection of Filtered Tc-99m Sulfur Colloid in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy (2005) (48)
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition (2018) (48)
Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. (2014) (47)
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon (2016) (47)
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy (2012) (47)
Predictors of systemic recurrence and disease‐specific survival after ipsilateral breast tumor recurrence (2005) (46)
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. (2019) (46)
Precision Oncology Decision Support: Current Approaches and Strategies for the Future (2018) (46)
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers (2017) (46)
Effective Local Control and Long-Term Survival in Patients with T4 Locally Advanced Breast Cancer Treated with Breast Conservation Therapy (2004) (46)
BRAF mutation testing with a rapid, fully integrated molecular diagnostics system (2015) (46)
Clinical next generation sequencing to identify actionable aberrations in a phase I program (2014) (45)
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes (2015) (45)
Attitudes toward molecular testing for personalized cancer therapy (2015) (45)
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA (2019) (45)
Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. (2004) (45)
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer (2020) (45)
Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. (2006) (44)
Regulation and localization of ribosomal protein S6 kinase 1 isoforms (2009) (44)
Incidence and Consequence of Close Margins in Patients with Ductal Carcinoma-In Situ Treated with Mastectomy: Is Further Therapy Warranted? (2013) (44)
Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer (2014) (43)
Frequency of mesenchymal‐epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide‐3‐kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer (2013) (43)
Molecular‐targeted nanotherapies in cancer: Enabling treatment specificity (2011) (43)
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response (2015) (42)
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study (2019) (42)
Impact of Identification of Internal Mammary Sentinel Lymph Node Metastasis in Breast Cancer Patients (2013) (42)
Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. (2019) (42)
Lymphovascular Invasion and Lobular Histology are Associated with Increased Incidence of Isolated Tumor Cells in Sentinel Lymph Nodes from Early-Stage Breast Cancer Patients (2008) (42)
Strategies for improving the management of immune-related adverse events (2020) (42)
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline‐ and nonanthracycline‐based regimens for HER2‐positive breast cancer (2012) (41)
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer (2018) (41)
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors (2017) (41)
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. (2018) (41)
Personalized cancer therapy—leveraging a knowledge base for clinical decision-making (2018) (41)
Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). (2006) (41)
Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer (2011) (40)
Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy (2008) (40)
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer (2017) (39)
Overview of the TREC 2019 Precision Medicine Track. (2019) (39)
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation (2009) (39)
Potential applicability of balloon catheter–based accelerated partial breast irradiation after conservative surgery for breast carcinoma (2004) (39)
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer (2017) (39)
Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow (2009) (39)
Challenges and perspective of drug repurposing strategies in early phase clinical trials (2015) (38)
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy (2016) (38)
Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site‐ and Sequence‐Specific Drug Release (2014) (37)
Delays in Primary Surgical Treatment Are Not Associated With Significant Tumor Size Progression in Breast Cancer Patients (2011) (37)
High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers (2009) (37)
Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation (2009) (37)
Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. (2017) (37)
First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. (2020) (37)
Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. (2019) (37)
RNA-binding specificity of Y-box protein 1 (2009) (36)
Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. (2015) (36)
Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy (2017) (36)
Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer (2012) (36)
Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study (2019) (36)
CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study. (2019) (35)
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced/Metastatic Solid Tumors or Lymphomas. (2021) (35)
Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma (2005) (35)
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. (2018) (35)
Bias from removing read duplication in ultra-deep sequencing experiments (2014) (35)
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors (2016) (35)
Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction (2016) (35)
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers (2016) (34)
Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. (2019) (34)
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. (2013) (34)
Improving the detection of patients with inherited predispositions to hematologic malignancies using next‐generation sequencing‐based leukemia prognostication panels (2018) (33)
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (2021) (33)
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy (2009) (33)
A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L). (2018) (33)
Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. (2008) (33)
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study. (2021) (33)
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. (2011) (33)
Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations. (2020) (32)
Functional consequence of the MET-T1010I polymorphism in breast cancer (2014) (32)
"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. (2017) (32)
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies (2020) (32)
Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents (2014) (31)
High-resolution fiber optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node metastases in breast cancer: a pilot study (2010) (31)
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer (2019) (31)
Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients (2020) (31)
Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). (2011) (31)
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. (2015) (31)
1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study (2017) (31)
Signature program: a platform of basket trials (2018) (31)
Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors. (2016) (30)
SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. (2011) (30)
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. (2015) (30)
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. (2016) (30)
Does Blue Dye Contribute to Success of Sentinel Node Mapping for Breast Cancer? (2010) (30)
The rapamycin-regulated gene expression signature determines prognosis for breast cancer (2009) (30)
Cancer Risk Management Decisions of Women with BRCA1 or BRCA2 Variants of Uncertain Significance (2011) (30)
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer (2021) (29)
Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations (2018) (29)
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. (2015) (29)
Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective? (2006) (29)
Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. (2007) (29)
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial (2019) (29)
Expression of sigma 1 receptor in human breast cancer (2004) (29)
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit (2014) (28)
Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. (2019) (28)
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma (2017) (28)
Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy (2013) (28)
Prognostic value of initial clinical disease stage after achieving pathological complete response. (2008) (28)
First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer (2019) (28)
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion (2016) (27)
High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype (2016) (27)
Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report (2016) (27)
Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers (2017) (27)
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial (2019) (27)
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. (2015) (27)
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. (2022) (27)
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers. (2018) (27)
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). (2016) (27)
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (2021) (27)
Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. (2014) (27)
Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders (2014) (27)
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial (2014) (27)
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer (2014) (26)
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors (2013) (26)
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. (2014) (26)
Identification of frequent somatic mutations in inflammatory breast cancer (2017) (26)
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. (2018) (26)
Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged ≤55 years (2008) (25)
Clinical Use of Precision Oncology Decision Support. (2017) (25)
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial (2017) (25)
Impact of concurrent proliferative high‐risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast‐conserving therapy (2006) (25)
Molecular therapeutics: promise and challenges. (2004) (25)
Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer (2019) (24)
Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome (2008) (24)
Feasibility of breast‐conserving surgery for patients with breast carcinoma associated with nipple discharge (2004) (24)
Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue (2011) (24)
Attitudes regarding privacy of genomic information in personalized cancer therapy. (2013) (24)
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden (2018) (24)
Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry. (2020) (24)
Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types (2016) (24)
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. (2017) (23)
Heterogenic Loss of BRCA in Breast Cancer: The “Two-Hit” Hypothesis Takes a Hit (2007) (23)
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials (2018) (23)
Epithelial to mesenchymal transition is associated with rapamycin resistance (2015) (23)
Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy (2007) (23)
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. (2017) (23)
Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations. (2015) (22)
A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas. (2016) (22)
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors (2017) (22)
Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). (2013) (22)
Challenges with biomarkers in cancer drug discovery and development (2018) (22)
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ (2012) (22)
Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer (2012) (22)
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer (2021) (21)
Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma. (2017) (21)
Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis (2019) (21)
Multifocality and multicentricity in breast cancer and survival outcomes. (2012) (21)
Patient knowledge and information-seeking about personalized cancer therapy (2016) (21)
Role of PI3K/AKT/mTOR in Cancer Signaling (2018) (21)
Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. (2009) (20)
Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's. (2018) (20)
A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors. (2020) (20)
Other Primary Malignancies in Breast Cancer Patients Treated with Breast Conserving Surgery and Radiation Therapy (2013) (20)
Decreased TGFβ signaling and increased COX2 expression in high risk women with increased mammographic breast density. (2009) (20)
Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov (2016) (20)
Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology. (2019) (20)
Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. (2016) (20)
Genotype–Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers (2015) (20)
Toward nodal staging of axillary lymph node basins through intradermal administration of fluorescent imaging agents. (2013) (20)
Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. (2011) (20)
Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET) (2007) (20)
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers (2020) (20)
The immunogenomic landscape of resected intrahepatic cholangiocarcinoma (2021) (20)
Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis (2018) (20)
Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. (2013) (19)
Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. (2006) (19)
Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion. (2020) (19)
Clinical outcomes based on multigene profiling in metastatic breast cancer patients (2016) (19)
Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). (2014) (19)
Searching for cancer-related information online: Unintended retrieval of complementary and alternative medicine information (2005) (19)
Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes (2013) (18)
Automated identification of molecular effects of drugs (AIMED) (2016) (18)
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. (2015) (18)
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. (2022) (18)
Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway. (2017) (18)
EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. (2017) (18)
Disseminated Tumor Cells in Biologic Subtypes of Stage I–III Breast Cancer Patients (2010) (18)
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials (2016) (18)
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor (2018) (18)
The Effect of Leucine Restriction on Akt/mTOR Signaling in Breast Cancer Cell Lines In Vitro and In Vivo (2011) (17)
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. (2019) (17)
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial (2019) (17)
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic (2018) (17)
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. (2015) (17)
Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC). (2018) (17)
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience (2016) (17)
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study (2021) (17)
Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications (2019) (16)
Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. (2009) (16)
PI 3 K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer (2011) (16)
FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology. (2019) (16)
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. (2020) (16)
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models (2021) (16)
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity (2020) (15)
Associations between the gut microbiome and fatigue in cancer patients (2021) (15)
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer (2018) (15)
OCTANE: Oncology Clinical Trial Annotation Engine. (2019) (15)
Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine (2019) (15)
Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. (2013) (15)
ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer. (2013) (15)
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. (2018) (15)
Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study (2022) (15)
Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers (2019) (15)
Inter-Observer Agreement for Quality Measures Applied to Online Health Information (2004) (15)
Abstract PD5-05: Neratinib forERBB2mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial (2016) (15)
Cancer driver mutation prediction through Bayesian integration of multi-omic data (2018) (15)
Abstract CT001: Neratinib inHER2orHER3mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study (2017) (15)
116MO Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2 (2020) (14)
Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. (2005) (14)
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials (2016) (14)
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC). (2016) (14)
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial (2021) (14)
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors (2021) (14)
AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results (2019) (14)
Breast conservation in breast cancer: surgical and adjuvant considerations (2004) (14)
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. (2017) (14)
Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017 (2014) (14)
Determinants of mastectomy in breast conservation therapy candidates. (2005) (14)
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study. (2021) (14)
Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. (2021) (14)
Abstract PD2-08: Neratinib + fulvestrant inERBB2-mutant, HER2–non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial (2017) (14)
FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells (2019) (13)
Prospective Clinical Sequencing of Adult Glioma (2019) (13)
COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission (2020) (13)
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss (2020) (13)
Phase 1 dose escalation of ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers. (2017) (13)
Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements (2021) (13)
Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors. (2017) (13)
Two birds with one stone: octreotide treatment for acromegaly and breast cancer. (2013) (13)
OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study (2021) (13)
Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study. (2016) (13)
Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer. (2018) (13)
Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion. (2016) (13)
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer (2020) (13)
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (12)
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies (2021) (12)
Next-generation sequencing for the general cancer patient. (2019) (12)
LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study (2021) (12)
Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers. (2017) (12)
54P Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2) (2020) (12)
Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literature (2015) (12)
PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors (2017) (12)
Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC). (2020) (12)
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study (2019) (12)
Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations (2019) (12)
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib (2019) (12)
The effects of metformin on pathologic complete response (pCR) rates in diabetic breast cancer (BC) patients receiving neoadjuvant systemic therapy (NST) (2008) (12)
High Risk of Contralateral Breast Carcinoma in Women With Hereditary/Familial Non-BRCA1/BRCA2 Breast Carcinoma (2007) (12)
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory (2017) (12)
Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus. (2015) (12)
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience (2015) (12)
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies (2016) (12)
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF‐mutated melanoma and other advanced malignancies (2018) (11)
Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. (2018) (11)
Physician interpretation of genomic test results and treatment selection (2018) (11)
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. (2023) (11)
ClinSeK: a targeted variant characterization framework for clinical sequencing (2015) (11)
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials (2023) (11)
Feasibility of Axillary Reverse Mapping During Sentinel Lymph Node Biopsy in Breast Cancer Patients (2010) (11)
Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy. (2005) (11)
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers (2021) (11)
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors (2021) (11)
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. (2019) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Career track of Society of University Surgeons Resident Research Award recipients. (2013) (10)
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial (2020) (10)
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma (2020) (10)
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers (2022) (10)
Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC). (2018) (10)
NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss. (2018) (10)
Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs (2017) (10)
Clinically relevant inflammatory breast cancer patient-derived xenograft–derived ex vivo model for evaluation of tumor-specific therapies (2018) (10)
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study (2019) (10)
HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. (2019) (10)
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers (2019) (9)
Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy. (2020) (9)
Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations. (2017) (9)
Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors. (2014) (9)
Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival (2010) (9)
Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. (2014) (9)
Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors. (2019) (9)
Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial. (2022) (9)
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. (2020) (9)
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience (2016) (9)
LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial (2021) (9)
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions (2019) (9)
Abstract PD3-13: Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (2018) (9)
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. (2021) (9)
Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer. (2018) (9)
Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations (2019) (9)
Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. (2015) (9)
MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. (2021) (9)
Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. (2020) (9)
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass (2012) (8)
Molecular determinants of post-mastectomy breast cancer recurrence (2018) (8)
Frequency of MET and PIK3CA copy number elevation and correlation with outcome in early stage breast cancer (2013) (8)
OT1-03-01: A Randomized Phase III Clinical Trial of Standard Adjuvant Endocrine Therapy +/− Chemotherapy in Patients (pts) with 1–3 Positive Nodes, Hormone Receptor (HR)-Positive and HER2−Negative Breast Cancer with Recurrence Score (RS) of 25 or Less: SWOG S1007. (2011) (8)
Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors. (2016) (8)
The impact of tumor heterogeneity on patient treatment decisions. (2013) (8)
Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel (2016) (8)
Integrated transcriptomic–genomic tool Texomer profiles cancer tissues (2019) (8)
TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC). (2021) (8)
Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors (2020) (8)
Artificial intelligence in clinical and translational science: Successes, challenges and opportunities (2021) (8)
Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual (2016) (8)
Translation Initiation Factor 4E (eIF4E): Prognostic Marker and Potential Therapeutic Target (2008) (8)
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer (2021) (8)
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) (2019) (8)
A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC). (2016) (8)
Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC). (2017) (8)
CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC). (2020) (8)
Correction: Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas (2015) (8)
Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer (2018) (8)
Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosin–Stained Sections of Core-Needle Biopsy Specimens (2020) (8)
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC) (2016) (8)
Adapting a Natural Language Processing Tool to Facilitate Clinical Trial Curation for Personalized Cancer Therapy (2014) (8)
Genotype in BRCA‐associated Breast Cancers (2013) (8)
Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial (2022) (7)
Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed? (2013) (7)
Oncology research using electronic medical record data. (2010) (7)
Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. (2015) (7)
Antibody-Drug Conjugates: Patient and Treatment Selection. (2020) (7)
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. (2022) (7)
Abstract CT238: TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A Phase I study (2019) (7)
Abstract PD3-06: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT trial (2019) (7)
Abstract CT024: Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations (2018) (7)
Axillary Reverse Mapping (ARM): A New Concept to Identify and Enhance Lymphatic Preservation (2008) (7)
Cancer Therapy : Clinical Loss of HER 2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes (2009) (7)
Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases after a Positive Sentinel Node Biopsy (2007) (7)
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer (2021) (7)
Impact of immune checkpoint inhibitor dose on toxicity, response rate, and survival: A pooled analysis of dose escalation phase 1 trials. (2018) (7)
False Negative Rate of Sentinel Lymph Node Biopsy in Multicentric and Multifocal Breast Cancers May be Higher in Cases with Large Additive Tumor Burden (2009) (7)
Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study (2019) (6)
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes (2020) (6)
Currency of Online Breast Cancer Information (2007) (6)
Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. (2018) (6)
Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors (2021) (6)
Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations (2015) (6)
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines (2022) (6)
Clinical outcomes based on multigene profiling in metastatic breast cancer patients. (2015) (6)
The characteristics of ARID1A mutations in colorectal cancer. (2018) (6)
FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies (2021) (6)
FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy. (2016) (6)
Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway. (2017) (6)
Abstract 4997: Responsiveness to immune checkpoint inhibitors in RET dependent cancers (2019) (6)
Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. (2014) (6)
Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations. (2021) (6)
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma (2022) (6)
Abstract B27: A phase I dose escalation study of the MDM2 inhibitor DS-3032b in patients with advanced solid tumors and lymphomas (2015) (6)
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF(V600E) Mutation (6)
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers (2018) (6)
Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer (2011) (6)
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non-Small-Cell Lung Cancer. (2019) (6)
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer (2021) (5)
Antibody-drug conjugates in lung cancer: dawn of a new era? (2023) (5)
Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway. (2017) (5)
ACOSOG Z1041 (Alliance): Cardiac events (CE) among those receiving neoadjuvant anthracyclines (A) and taxanes with trastuzumab (T) for HER2+ breast cancer. (2013) (5)
Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing (2021) (5)
Cancer gene profile of metastatic breast cancer. (2012) (5)
Erratum: Ability to generate patient-derived breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes (PLoS ONE (2015) 10:9 (e0136851) DOI: 10.1371/journal.pone.0136851) (2016) (5)
Whole exome sequencing of metaplastic breast cancer (MpBC): Effect of mutation status on survival. (2017) (5)
Is immuno-oncology therapy effective in hypermutator glioblastomas with somatic or germline mutations? (2019) (5)
Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial. (2022) (5)
Abstract P6-20-02: Activity of larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase, in TRK fusion breast cancers (2019) (5)
A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer (2015) (5)
A phase 1 dose escalation study of eFT508, an inhibitor of mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK-1) and MNK-2 in patients with advanced solid tumors. (2017) (5)
Abstract 974: Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification (2021) (5)
Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120. (2019) (5)
MA03.02 TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors (2021) (5)
Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study (2022) (5)
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer (2017) (5)
Segal and Dowsett , p . 1724 Emergence of Constitutively Active Estrogen Receptor-a Mutations in Pretreated Advanced Estrogen Receptor – Positive Breast Cancer (2014) (5)
A phase IIa clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification (2019) (5)
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial (2021) (5)
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations (2021) (5)
NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—A phase 1/2 clinical trial. (2021) (5)
SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors. (2020) (5)
Whole Genome Sequencing in Cancer Clinics (2014) (5)
Dose‐escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF‐mutated advanced cancers (2020) (5)
Abstract CT016: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors (2021) (5)
Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience (2017) (5)
Postive sentinel nodes after neoadjuvant chemotherapy: What factors predict additional disease in the axilla? (2006) (5)
255PPhase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers (2017) (4)
Abstract C49: Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors (2015) (4)
Sentinel lymph node dissection is technically feasible in older breast cancer patients. (2010) (4)
Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing (2019) (4)
Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. (2021) (4)
Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. (2021) (4)
Abstract P4-04-08: Genomic profiling of 304 treatment-naïve Chinese breast cancer patients: A comparison of Chinese and TCGA cohorts (2019) (4)
Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. (2019) (4)
The natural course of hypermutator gliomas. (2018) (4)
First-inhuman trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients (2018) (4)
The role of surgeons in building a personalized medicine program (2015) (4)
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma (2021) (4)
Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy (2007) (4)
Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes (2016) (4)
RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient (2021) (4)
Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer. (2009) (4)
Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial (2020) (4)
FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions/rearrangements. (2021) (4)
Cancer-related Complementary and Alternative Medicine Online: Factors Affecting Information Retrieval (2004) (4)
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study (2021) (4)
Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma (2018) (4)
Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. (2013) (4)
Exposure to anti‐PD‐1 causes functional differences in tumor‐infiltrating lymphocytes in rare solid tumors (2019) (4)
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. (2020) (4)
Locoregional Outcomes and Radiotherapy Response in Patients with Triple-negative Breast Cancer (2009) (4)
Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns. (2020) (4)
Erratum to "Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies" [Oncotarget., 6 (2015) 12809-12821] (2015) (4)
TAK228 enhances antitumor activity of eribulin in triple negative breast cancer (2019) (4)
Next generation sequencing for biliary tract cancers (2021) (4)
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study (2021) (4)
Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations inBRCA1/2, mutations/deletions inPTENor PTEN loss, aberrations in otherBRCApathway genes, and germline mutations inBRCA1/2(not breast or ovarian cancer) (2018) (4)
1039TiPPhase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma (2017) (4)
Natural Language Processing–Assisted Literature Retrieval and Analysis for Combination Therapy in Cancer (2022) (4)
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors (2022) (4)
The prevalence of KRASG12C mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer. (2020) (4)
O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study* (2021) (4)
Re-evaluating the efficacy of axillary ultrasound in the detection of nodal metastasis and its impact on clinical practice. (2011) (3)
MK-2206 window of opportunity study in breast cancer. (2018) (3)
AB045. P-13. Genomic heterogeneity between Asian and Western intrahepatic cholangiocarcinoma (2019) (3)
Nomogram to predict sentinel lymph node involvement in patients with clinically node-negative breast cancer receiving neoadjuvant chemotherapy. (2012) (3)
Abstract B105: Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas (2019) (3)
Impact of PI3K aberrations on efficacy of perifosine (P), x-PECT: A phase III randomized study of P plus capecitabine (PC) versus placebo plus capecitabine (C) in refractory metastatic colorectal cancer (mCRC) patients. (2014) (3)
Serum Proteomics for BRCA1-associated Breast Cancer (2004) (3)
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. (2022) (3)
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified (2021) (3)
Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers. (2015) (3)
Abstract 5148: CanDrA: Cancer-specific driver missense mutation annotation with optimized features. (2013) (3)
Cancer risk management decisions of women with BRCA variants of uncertain significance (2008) (3)
Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation. (2018) (3)
Targeting translation initiation in breast cancer (2014) (3)
Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers. (2014) (3)
Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. (2018) (3)
Abstract 4038: Exploring optimal targeted combination therapies with neratinib for HER2+ breast cancer (2017) (3)
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid Tumors (2020) (3)
Activation of the PI3K/AKT signal transduction pathway is inversely associated with estrogen receptor levels and correlates with survival in hormone receptor-positive Her2/neu-negative breast cancer (2007) (3)
Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. (2016) (3)
Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer (2022) (3)
The clinical impact of proliferative high-risk lesions presenting concurrently with ductal carcinoma in situ (DCIS) in patients (pts) treated with breast conserving therapy (BCT) (2005) (3)
Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors. (2016) (3)
Reliability and Evaluation of Health Information Online (2007) (3)
PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery (2022) (3)
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study (2021) (3)
ESR1 mutations provide novel targets for breast cancer immunotherapy. (2020) (3)
Erratum: Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012;118:1515-22. (2014) (3)
Reply to K.J. Van Zee et al (2012) (3)
Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes. (2017) (3)
Rapamycin-mTOR+BRAF=? Using relational similarity to find therapeutically relevant drug-gene relationships in unstructured text (2019) (3)
Value of adjuvant radiation therapy in breast cancer patients with one to three positive lymph nodes undergoing a modified radical mastectomy and systemic therapy. (2009) (3)
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences (2022) (3)
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. (2022) (3)
Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study. (2016) (3)
Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study. (2022) (3)
Surgical Options for Breast Cancer (2008) (3)
Abstract OT2-06-01: A phase-2 trial of neoadjuvant alpelisib and nab-paclitaxel in anthracycline refractory triple negative breast cancers with PIK3CA or PTEN alterations (2020) (3)
Early CgA Response as Predictor of Outcome Following Everolimus Therapy Among Patients With Low- to Intermediate- Grade Neuroendocrine Carcinoma: Analyses of a Single Institution Phase II Study (2010) (3)
OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients (2019) (3)
Intra-Individual Comparison of Lymphatic Drainage Patterns Using Subareolar and Peritumoral Isotope Injection for Breast Cancer (2009) (3)
NCI 9448: Phase I study of trametinib in combination with chemoradiation for KRAS-mutant non-small cell lung cancer. (2015) (3)
Abstract S3-06: Emergence of constitutively active estrogen receptor mutations in advanced estrogen receptor positive breast cancer (2013) (2)
Abstract 2413: Rapid, automated BRAF mutation testing of cell-free DNA from plasma of patients with advanced cancers using the novel Idylla platform (2015) (2)
237 Impact of phase 1 expansion cohorts on probability of success in phase 2 and time-to-drug-approval: analysis of 385 new drugs in oncology (2014) (2)
Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer (2017) (2)
A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). (2017) (2)
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial (2022) (2)
Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy (2021) (2)
Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. (2016) (2)
Abstract P3-14-02: Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab (2016) (2)
A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations. (2016) (2)
Significant Activity of the mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma Patients (2013) (2)
Abstract LB-185: Preliminary results of PROCLAIM-CX-2009, a first-in-human, dose-finding study of the Probody drug conjugate CX-2009 in patients with advanced solid tumors (2019) (2)
Abstract C120: Genomic landscape in advanced metaplastic breast cancer and outcomes with mTOR targeted therapy. (2013) (2)
Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center. (2015) (2)
PDXNet Portal: Patient-Derived Xenograft model, data, workflow, and tool discovery (2021) (2)
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study (2021) (2)
Erratum: Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity (Cancer Cell (2019) 36(4) (444–457.e7), (S1535610819303848), (10.1016/j.ccell.2019.09.001)) (2020) (2)
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. (2022) (2)
Haplotype Analysis of the TRB Locus by TCRB Repertoire Sequencing (2018) (2)
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies (2021) (2)
58P Quality of life (QoL) outcomes with futibatinib treatment in FOENIX-CCA2 - A phase II study in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions/rearrangements (2020) (2)
Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression. (2018) (2)
Impact of chemotherapy timing on local-regional failures in patients with breast cancer undergoing breast-conserving therapy. (2011) (2)
Impact of Progression during Neoadjuvant Chemotherapy on Operative Management of Breast Cancer. (2009) (2)
Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (2)
Abstract 4970: Oxidative phosphorylation as a target in triple negative breast cancer therapy (2017) (2)
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers (2023) (2)
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: A guide to the selective carcinoma in situ (2004) (2)
Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection. (2013) (2)
Abstract PD06-08: Size Matters: Incorporation of Sentinel Lymph Node (SLN) Metastasis Size into a Nomogram Predicting NonSLN Involvement in SLN Positive Breast Cancer Patients (2010) (2)
Rapamycin-regulated gene expression signature determines prognosis in breast cancer. (2009) (2)
397 Intra-tumor immunotherapy injections utilizing image guidance in interventional radiology: clinical trial experience at a tertiary care cancer center (2020) (2)
Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing. (2017) (2)
Precision medicine: Preliminary results from the initiative for molecular profiling and advanced cancer therapy 2 (IMPACT 2) study (2019) (2)
Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation. (2013) (2)
52P Assessment of futibatinib exposure–response (E–R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA) (2021) (2)
Genomic alterations driving breast cancer (BC) metastases and their relationship with the subtype switch in the GEICAM ConvertHER study. (2017) (2)
Outcomes of patients with gene fusion driven cancers treated on early phase clinical trials. (2018) (2)
Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer. (2015) (2)
Abstract 682: Increased stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients (2012) (2)
Residual cancer burden (RCB) in breast cancer patients treated with taxane- and anthracycline-based neoadjuvant chemotherapy: The effect of race. (2010) (2)
Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer (2019) (2)
Targeted next generation sequencing of sarcomas for identification of therapeutic targets. (2013) (2)
Abstract 1655: Discovery and development of IACS-010759, a novel inhibitor of Complex I currently in phase I studies to exploit oxidative phosphorylation dependency in acute myeloid leukemia and solid tumors (2018) (2)
Detection and description of ERBB2 amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC). (2018) (2)
P2-08-02: Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017). (2011) (2)
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. (2009) (2)
Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary. (2017) (2)
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models (2021) (2)
Impact of low estrogen- and progesterone-receptor expression on survival outcomes in breast cancers previously classified as triple-negative breast cancers. (2011) (2)
A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy. (2019) (2)
Abstract OT1-14-01: Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)-expressing cancers, including breast cancer: A phase 1b/2, multicenter, open-label, dose-finding and cohort-expansion study (ZWI-ZW25-204) (2022) (2)
1124P Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience (2020) (2)
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology (2022) (2)
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit (2016) (2)
A functional genomic approach to actionable gene fusions for precision oncology (2022) (2)
Abstract P1-07-06: Effect of biospecimen variables on proteomic biomarker assessment in breast cancer (2012) (2)
Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort (2020) (2)
Ultra-deep next-generation sequencing of plasma cell-free (cf) DNA from patients with advanced cancers. (2015) (2)
Sentinel lymph node dissection provides similar local-regional control compared to axillary dissection in patients with node negative breast cancer (2005) (2)
OMICS AND PROGNSTIC MARKERS (2013) (1)
Molecular profiling by circulating tumor DNA (ctDNA) and benefit from anti-PD-1 in HCC. (2019) (1)
Abstract PS11-07: Intratumoral activation and phase 1/2 clinical activity of CX-2009, a probody drug conjugate (PDC) targeting CD166 (2021) (1)
Abstract 4772: Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing (2018) (1)
Abstract CT110: Olaparib (O) in patients (pts) with solid tumors with ATM mutation or deletion: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (2022) (1)
Sentinel lymph node biopsy accurately reflects nodal status following preoperative chemotherapy for breast cancer (2004) (1)
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification (2022) (1)
A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01). (2021) (1)
Abstract P3-07-04: EphA2: An emerging target in triple-negative breast cancer (2018) (1)
Abstract CT121: Phase I dose-escalation study of TAS-120, a highly selective, covalently bound FGFR inhibitor, in patients with advanced solid tumors (2018) (1)
Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers. (2022) (1)
Abstract P6-10-03: Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study (2023) (1)
Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT ‘basket’ trial (2019) (1)
Abstract LB012: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort (2021) (1)
Abstract LB-170: Droplet digital PCR detection and longitudinal monitoring of BRAF mutations in cell-free urinary DNA of patients with metastatic cancers or Erdheim-Chester disease (2014) (1)
Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (2022) (1)
Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance. (2018) (1)
Abstract CT052: A phase I dose escalation trial of vemurafenib in combination with the mTOR inhibitor everolimus for melanoma and non-melanoma cancers with a BRAF aberration (2016) (1)
Abstract P4-13-11: Everolimus, letrozole and trastuzumab in estrogen receptor and HER2-positive patients with metastatic breast cancer and other solid tumors: Evaluating synergy and overcoming resistance (2016) (1)
1 Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials (2014) (1)
RAS heterogeneity as a prognostic marker in metastatic colorectal cancer. (2017) (1)
Abstract S3-06: Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017 (2016) (1)
Modulation of breast cancer cell-free DNA with surgical resection. (2013) (1)
Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. (2021) (1)
Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies. (2015) (1)
Precision oncology in sarcoma drug development: Impact of genomic matching on response, clinical benefit, and survival in sarcoma patients on phase 1 trials. (2019) (1)
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials (2022) (1)
Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors. (2017) (1)
Abstract C203: BRAF and KRAS mutation testing in cell-free DNA and circulating tumor cells from blood of patients with metastatic cancers. (2013) (1)
Abstract 2689: Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study (2015) (1)
Abstract B177: Non-invasive tumor mutation detection of cell-free urinary DNA using massively parallel deep DNA sequencing. (2013) (1)
Abstract 3146: Circulating tumor DNA assay performance for detection and monitoring of KRAS mutations in urine from patients with advanced cancers (2016) (1)
ASBrS and ASO: A New Partnership Begins (2010) (1)
98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study (2022) (1)
Using citation analysis to ease information overload in oncology (2005) (1)
Demographics, tumor characteristics, and clinical outcomes associated with somatic mutations in 201 cancer-related genes in advanced melanoma patients (pts). (2015) (1)
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts (2021) (1)
404PDose escalation study of vemurafenib with crizotinib or sorafenib in patient with BRAF-mutated advance cancers (2017) (1)
Abstract 4700: One size does not fit all: Fingerprinting advanced carcinoma of unknown primary through comprehensive profiling identifies aberrant activation of the PI3K and MAPK signaling cascades in concert with impaired cell cycle arrest (2014) (1)
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) (2023) (1)
51P Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA) (2021) (1)
Abstract LB-231: Phase Ib dose escalation and biomarker study of MK2206 in combination with standard doses of weekly paclitaxel in patients with locally advanced or metastatic solid tumors with expansion in advanced breast cancer (2012) (1)
Ultra-sensitive detection of circulating tumor DNA identifies patients in high risk of recurrence in early stages melanoma (2019) (1)
Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo (2021) (1)
Patient-derived xenograft (PDX) models in basic and translational breast cancer research (2016) (1)
BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers. (2014) (1)
Clinical outcome for gastrointestinal cancers with polymerase epsilon mutations treated with immunotherapy. (2020) (1)
Genomic profiling of three pathways through molecular profiling-based assignment of cancer therapy (NCI- MPACT) (2019) (1)
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. (2016) (1)
First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors. (2022) (1)
Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting. (2018) (1)
Molecular Medicine in Practice PI 3 K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer (2011) (1)
Abstract CT103: Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors (2021) (1)
The incidence, prophylaxis and treatment of venous thromboembolism in patients undergoing breast cancer surgery. (2004) (1)
Hormone receptor (AR/ER/PR) expression as a prognostic marker and novel candidate for drug development across multiple tumor types. (2017) (1)
Resection of liver metastases from breast cancer: Effect of timing of surgery and estrogen receptor status on outcome. (2011) (1)
Running title: Functional proteomics of human breast tumors Title: A novel approach to the study of the functional proteome in breast cancer Running title: Functional proteomics of human breast tumors (2008) (1)
Incidence of immune-related adverse events in patients who received immunotherapy and radiographic analysis to predict pneumonitis (2016) (1)
Abstract A167: Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors (2018) (1)
Abstract B175: Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by droplet digital PCR. (2013) (1)
Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. (2015) (1)
SWI/SNF complex subunit aberrations in diverse cancers: Next-generation sequencing of 539 patients. (2017) (1)
Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation (2018) (1)
Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures (2022) (1)
283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs) (2020) (1)
Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial (2019) (1)
CT-based radiogenomic signature to identify isocitrate dehydrogenase (IDH)1/2 mutations in advanced intrahepatic cholangiocarcinoma. (2019) (1)
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors (2021) (1)
Abstract CT-03: Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer (2012) (1)
Characterization of KEAP1-NRF2 genomic alterations across diverse tumor types: Co-occurring alterations, survival outcomes, and implications for targeting cancer metabolism. (2018) (1)
Abstract OT1-03-04: INTERACT- INTegrated Evaluation of Resistance and Actionability using Circulating Tumor DNA in hormone receptor (HR) positive metastatic breast cancers (MBC) (2019) (1)
A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02) (296) (2022) (1)
Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience. (2014) (1)
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study (2021) (1)
Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy (2013) (1)
Abstract 734: Monitoring of dynamic changes and clonal evolution in circulating tumor DNA from patients with IDH-mutated cholangiocarcinoma treated with IDH inhibitors (2020) (1)
Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer. (2015) (1)
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers. (2017) (1)
Abstract B26: Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies. (2013) (1)
Local-regional and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies. (2009) (1)
Women’s triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (NACT). (2015) (1)
Ductal Carcinoma In Situ: Risk Factor or Cancer (2018) (1)
Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors. (2017) (1)
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers (2022) (1)
Utility of a One-Step Nucleic Acid Amplification (OSNA) Assay for Comprehensive Examination of Axillary Lymph Nodes in Breast Cancer. (2009) (1)
Abstract 5682: Synergism of PARP inhibitor and MET inhibitor in multiple cancer types with intrinsic and acquired PARP inhibitor resistances (2020) (1)
Abstract 3075: Nuclear export inhibitor selinexor (KPT-330) demonstrates anti-tumor efficacy alone and in combination with chemotherapy in multiple breast cancer models (2016) (1)
Abstract 5399: Investigating phenotypic plasticity in breast cancer with high-throughput nanogrid single-nucleus RNA sequencing (2017) (1)
Activation of hedgehog pathway in neuroendocrine tumors. (2012) (1)
Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision medicine. (2014) (1)
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations (2022) (1)
Abstract 2414: Novel, ultra deep next-generation sequencing of plasma cell-free DNA from patients with advanced cancers (2015) (1)
Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. (2021) (1)
Outcomes differences in tumors < 1 cm by age and breast cancer subtype. (2010) (1)
A phase I study of the anti-IGF-1R monoclonal antibody (MoAb), IMC-A12 (I), and everolimus (E) in well-differentiated neuroendocrine tumors (WD NET). (2014) (1)
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102) (2022) (1)
Abstract CT029: Safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC) (2022) (1)
Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response. (2014) (1)
Abstract P6-11-11: Multistage Delivery of Paclitaxel: Increased Drug Stability and Sustained Release Results in Enhanced Efficacy in Breast Cancer (2012) (1)
Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. (2013) (1)
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer (2023) (1)
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition (2021) (1)
Abstract PD13-08: PD13-08 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/HER2–Negative Breast Cancer (BC) (2023) (1)
1869TiP A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02) (2021) (1)
Abstract CT076: Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (2016) (1)
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials (2020) (1)
Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study (2022) (1)
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. (2022) (1)
A path to translation: How 3D patient tumor avatars enable next generation precision oncology. (2022) (1)
Intramammary lymph node metastases are an independent predictor in breast cancer outcomes (2004) (1)
Abstract 5584: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (IdyllaTM) (2014) (1)
Routine use of sentinel lymph node surgery in patients undergoing prophylactic mastectomy: A decision analysis model. (2006) (1)
169 BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylla™) (2014) (1)
77P Clinical characteristics and therapeutic implications of PALB2 variants in patients with advanced solid tumors (2020) (0)
91P Liquid biopsy for detection of minimal residual disease after liver metastasectomy in stage IV colorectal cancer (2021) (0)
Abstract LB057: Whole exome sequencing of tumor tissue and circulating tumor DNA ingastrointestinal stromal tumors (GIST) (2021) (0)
Abstract OT-34-01: Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive metastatic breast cancer withPIK3CAmutation orPTENmutation (2021) (0)
Feasibility of the use of primary breast epithelial cell cultures to identify genotype-specific preventive agents (2005) (0)
Natural history and characteristics of ERBB2-mutated hormone receptor-positive advanced breast cancer: a retrospective case-control study from AACR Project GENIE. (2022) (0)
Abstract A199: Association of immune checkpoint inhibitor dose and survival in phase I clinical trials: is it time to redefine the recommended phase II dose (2018) (0)
Abstract 642: Detection of circulating antibodies against KRAS in patients with advanced cancers (2017) (0)
Rapamycin synergistically enhances the cytotoxicity of paclitaxel in breast cancer cells (2004) (0)
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study (2023) (0)
Abstract 3432: Ataxia-telangiectasia mutated loss of function displays variant and tissue specific differences across tumor types (2023) (0)
Abstract 3215: ClinGen somatic cancer working group: Disseminating standardized cancer molecular diagnostic data and evidence through global collaboration and expert curation (2020) (0)
The Effect of Immediate Breast Reconstruction on Postmastectomy Irradiation (2005) (0)
Abstract 1118: Absence of mouse-specific tumor evolution in patient-derived cancer xenografts (2020) (0)
46. ClinGen somatic cancer working group: Enhancing standardized interpretation of cancer genetic data for clinical use (2020) (0)
Abstract CT109: Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR pathway alterations (2021) (0)
Abstract 4881: Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347 (2019) (0)
Impact on overall survival of primary tumor extirpation in breast cancer patients who present with stage IV disease (2007) (0)
Abstract C016: Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer (2019) (0)
Activating PIK3CA and AKT mutations in triple-receptor-negative breast cancer (2007) (0)
Evaluation of the stage IB designation of the 7th edition of the AJCC Staging System. (2012) (0)
The role of GSK3β in rapamycin-mediated cell cycle regulation (2005) (0)
Prognostic factors in RET dependent cancers treateded with RET inhibitors in early phase clinical trials. (2021) (0)
Clinical next-generation sequencing in sarcomas. (2016) (0)
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy (2012) (0)
Abstract 1792: FGFR3 mediated PARP1 tyrosine 158 phosphorylation promotes PARP inhibitor resistance (2022) (0)
Re-evaluating eligibility criteria: Analysis of factors leading to nonparticipation and outcomes of patients (pt) with advanced cancer who signed consent but were not treated in early-phase immunotherapy (IO) trials. (2019) (0)
Abstract 2343: Comprehensive evaluation of antibody-drug conjugate targets for drug development across tumor types: Analysis from TCGA (2018) (0)
Abstract 3668: Multistage delivery of RNA interfering nanotherapeutics targeting the PI3K/Akt/mTOR pathway (2015) (0)
Abstract PO-133: Breast tumors maintain a reservoir of subclonal diversity during primary expansion (2020) (0)
Abstract 327: Antitumor efficacy of trastuzumab deruxtecan in combination with adavosertib in HER2-expressing Cyclin E amplified gastroesophageal cancers (2022) (0)
Abstract CT163: Temsirolimus in combinaton with metformin in patients with advanced or refractory endometrial cancers (2020) (0)
Building a predictive breast cancer risk model. (2007) (0)
Prescription trends of everolimus in non-elderly cancer patients with private insurance in the United States. (2017) (0)
Abstract 6180: Antitumor activity of the ATR inhibitor Elimusertib in patient-derived xenograft models with DNA damage response pathway alterations (2023) (0)
Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy. (2018) (0)
Author reply (0)
Abstract PD3-6: ConvertHER: Evolution of genomic alterations from primary to metastatic breast cancer (2015) (0)
Abstract P5-20-06: Phase 1 dose escalation with ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-high breast cancer (BC) (2018) (0)
Abstract P2-05-03: Anastrozole and everolimus in hormone receptor-positive metastatic breast cancer: Safety profile, activity and associations of molecular alterations in the PI3K/AKT/mTOR pathway (2015) (0)
Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity (2020) (0)
Abstract PS18-37: Loss of Trop2 protein in metaplastic carcinoma of breast by IHC (2021) (0)
Treatment patterns and systemic therapy outcomes for patients with salivary duct carcinoma and adenocarcinoma NOS. (2021) (0)
INNV-40. TARGETED NEXT GENERATION SEQUENCING OF PEDIATRIC HIGH-GRADE GLIOMA AND ITS THERAPEUTIC IMPLICATIONS, MD ANDERSON EXPERIENCE (2019) (0)
Circulating Tumor DNA Dynamics Predict Outcomes of Systemic Therapy in Patients with Advanced Cancers (2020) (0)
Effect of modest delays in primary surgical treatment on progression of tumor size in breast cancer patients. (2009) (0)
73P Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study (2020) (0)
Functional proteomic-based predictor of pathologic complete response to neoadjuvant chemotherapy with paclitaxel/FAC-FEC in breast cancer (2008) (0)
Breast cancer multifocality-multicentricity and locoregional recurrance. (2012) (0)
Abstract 4971: IACS-010759, a novel inhibitor of complex I in Phase I clinical development to target OXPHOS dependent tumors (2017) (0)
Investigating the disparate enrollment of older adults on phase I clinical trials: Evolving participation patterns of patients 65 years and older w advanced cancer on phase I trials. (2020) (0)
Abstract 3009: A systematic review of the tumor growth metrics of patient-derived xenograft (PDX) models in the literature and in NCI PDXNet centers (2021) (0)
P3-07-05: Nomogram Incorporating SLN Metastasis Size Provides the Most Accurate Prediction of Non-SLN Involvement in Breast Cancer Patients. (2011) (0)
Abstract B003: Combinatorial therapies of neratinib for HER2-amplified cancer (2019) (0)
Mutation enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced colorectal and other cancers. (2017) (0)
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. (2023) (0)
Cancer Positive Breast − in Pretreated Advanced Estrogen Receptor Mutations α Emergence of Constitutively Active Estrogen Receptor-Updated (2014) (0)
Abstract P4-08-05: NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer (2023) (0)
Multistage delivery of RNA interfering nanotherapeutics targeting the PI3K/Akt/mTOR pathway (2015) (0)
Exploring the Use of SemRep Predications to Help Identify Secondary Drug Targets for Personalized Cancer Therapy (2014) (0)
The rate of immediate reconstruction following mastectomy for breast cancer varies by patient race (2004) (0)
Hepatotoxicity in advanced cancer patients receiving immune-based cancer treatment. (2018) (0)
First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors. (2022) (0)
Abstract 3107: Identifying therapeutic vulnerabilities in HR-positive, HER2-negative advanced breast cancer patient-derived xenograft models refractory to CDK4/6 inhibition (2022) (0)
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. (2019) (0)
Comparison of Mutation Profile Among Responders and Non-Responders in a Cohort of Patients with Relapsed/Refractory Myeloid Malignancies Treated with MEK 1/2 Inhibitor Trametinib (2015) (0)
Abstract LB-B22: TNBC kinase prioritization for targeted therapy after chemotherapy resistance (2018) (0)
Contralateral prophylactic mastectomy: Efficacy and determinants of significant histologic findings (2004) (0)
Abstract PD6-02: The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer – Results from the ACOSOG Z1041 (Alliance) trial (2016) (0)
Oestrogen receptor coactivator AIB 1 is a marker of tamoxifen bene fi t in postmenopausal breast cancer (2013) (0)
Predictors of Persistent Micrometastatic Disease after Neoadjuvant Chemotherapy. (2009) (0)
526P Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3 (2021) (0)
Abstract A48: Phase I study of Everolimus (mTOR inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR,VEGFR,RET) in children, adolescents, and young adults with advanced solid tumors (2016) (0)
A phase I trial of pazopanib and vorinostat: The role of TP53 mutations. (2014) (0)
Abstract P1-11-22: Bisphosphonates and Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer (2010) (0)
31st Annual Meeting • American Society of Preventive Oncology, Houston, Texas • March 2–4, 2007 (2007) (0)
Combination Therapies Targeting the PI3K/AKT/mTOR Pathways (2016) (0)
Postmastectomy Radiation Therapy in Stage II-III Breast Cancer Patients <35 Years Old Treated with Doxorubicin-based Neoadjuvant Chemotherapy and Mastectomy (2005) (0)
Companion Diagnostics and Cancer Biomarkers Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer (2014) (0)
565P Selinexor in combination with topotecan in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study (2020) (0)
Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes. (2021) (0)
O13-6 Japanese subgroup analysis of datopotamab deruxtecan in NSCLC cohort of TROPION-PanTumor01, a phase 1 study (2022) (0)
Abstract 246: Phase 1 study: Ipilimumab (anti CTLA-4) in combination with Lenalidomide in patients with advanced cancers (2015) (0)
Abstract 2346: ARDE: Detecting selectively expressed cancer driver mutations through integration of exome and transcriptome sequencing data (2018) (0)
376 A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (2020) (0)
Abstract B17: Activating mutations of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene confer sensitivity to PD-L1 checkpoint inhibition in metastatic adenocarcinoma patients (2020) (0)
Abstract 1496: Epithelial to mesenchymal transition and rapamycin sensitivity in cancer cell lines. (2013) (0)
Abstract P1-01-04: Nodal patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy: Results of a secondary analysis of TBCRC 017 (2013) (0)
Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies. (2017) (0)
Characterization of patient-derived breast cancer xenografts demonstrates molecular evolution (2011) (0)
Reply to letter: "Waiting time for breast cancer treatment". (2014) (0)
MTOR Inhibitor MLN0128 has Antitumor Efficacy in Cell Lines With Intrinsic and Acquired Rapamycin-Resistance. (2013) (0)
Abstract P6-21-04: Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss (2019) (0)
GENE-29. DEEP PANEL SEQUENCING OF A PROSPECTIVELY COLLECTED GLIOMA COHORT (2017) (0)
DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations (2022) (0)
P1.09Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer (2015) (0)
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (2021) (0)
Abstract 2827: Association between new onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor (TKI) therapy in phase I clinical trials (2014) (0)
ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy – Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Positive Clinical Stage 2–3 Breast C (2023) (0)
HER kinase inhibition in patients with HER2- and HER3-mutant cancers (2018) (0)
Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status (2023) (0)
Decision Support for Genomically-Informed Cancer Therapy (2019) (0)
Abstract PR05: Investigating the importance of low allele frequency mutations for cancer patient management (2015) (0)
Abstract PR10: PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers (2020) (0)
Abstract P6-11-03: Site-Specific, Concomitant Delivery of Rapamycin and Paclitaxel in Breast Cancer: Consequent Synergistic Efficacy Enhancement (2012) (0)
Repeat large panel genomic sequencing identifies actionable alterations and characterizes the genomic landscape in patients with metastatic solid tumors. (2022) (0)
Factors leading to the decision for contralateral prophylactic mastectomy in patients with breast cancer. (2009) (0)
Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts). (2016) (0)
Abstract 4017: TAS2940 inhibits intracranial tumor growth and prolongs survival in HER2-aberrant and EGFR-amplified patient-derived xenograft models (2023) (0)
P4-09-09: Expression of c-MET and Phospho c-MET in Breast Cancers by Subtype and Its Impact on Survival Outcomes. (2011) (0)
Opioid prescriptions after breast cancer surgery: Perception and reality. (2018) (0)
Racial differences in attitudes toward molecular testing for personalized cancer therapy. (2013) (0)
Outcomes and the impact of genomic characteristics on patients with metastatic urothelial carcinoma enrolled in early phase trials. (2020) (0)
Abstract 557: Novel targeted combination therapies active in KRAS mutant non-small cell lung cancer (NSCLC) identified using patient-derived xenografts (PDX) (2020) (0)
Abstract PD9-09: Molecular differences between younger versus older estrogen receptor positive/human epidermal growth factor receptor-2 negative breast cancers (2023) (0)
Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor. (2016) (0)
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression (2019) (0)
TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes. (2018) (0)
Abstract LB-170: Single cell sequencing identifies clonal stasis and punctuated copy number evolution in triple-negative breast cancer patients (2015) (0)
Conventional cautions regarding online information: Do they predict accuracy of breast cancer websites? (2006) (0)
Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. (2014) (0)
Activated autologous dendritic cells injected intratumorally are able to overcome local and systemic immune suppression imposed by the tumor and its microenvironment (2014) (0)
Breast conservation therapy in T4 locally advanced breast cancer: Effective local control with long-term survival (2004) (0)
Targeted next generation sequencing in well-differentated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations. (2015) (0)
Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC). (2020) (0)
Systematic Functional Ann otation of Somatic Mutations in Cancer Graphical (2018) (0)
Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers. (2017) (0)
Off-label use of everolimus and associated factors in non-elderly cancer patients with private insurance in the United States. (2018) (0)
Toward Personalized Therapy for Cancer (2015) (0)
HER2 studies look promising (2011) (0)
A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies. (2014) (0)
Abstract P4-11-15: Outcomes for Breast Cancer Patients with Isolated Metastasis or Recurrence to the Contralateral Nodal Basins (2010) (0)
Abstract OT3-08-01: A phase 1 trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer (aBC) and other solid tumors (PIKASSO-01, trial in progress) (2023) (0)
Translational Research from an Informatics Perspective (2007) (0)
Abstract P1-16-04: Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis (2018) (0)
Molecular Cancer apeutics linical Development amycin Regulates Stearoyl CoA Desaturase 1 Ther ression in Breast Cancer (2010) (0)
Front & Back Matter (2012) (0)
Abstract 676A: Overcoming PARP inhibitor resistance with molecularly guided rational combinations in triple-negative breast cancer patient-derived xenograft models (2020) (0)
Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (2022) (0)
Abstract P5-08-12: Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterations (2022) (0)
ASO Visual Abstract: Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy (2021) (0)
1509MO Adherence to the Food and Drug Administration (FDA) guidance for the co-development of two or more investigational new drugs in phase 1/2 cancer trials (2021) (0)
POSA354 Patient-Reported Outcomes in Futibatinib-Treated Intrahepatic Cholangiocarcinoma Patients with FGFR2 Fusions/Rearrangements: Results from the Foenix-CCA2 Study (2022) (0)
170 Novel, ultra-deep next-generation sequencing for BRAF mutation testing using small amount of cell-free DNA from plasma of patients with advanced cancers (2014) (0)
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma (2022) (0)
The Lannin/Haffty article reviewed (2004) (0)
Site-specific time and sequential nanoparticle delivery of chemotherapeutics for synergy enhancement (2015) (0)
Modeling Breast Cancer Heterogeneity With Patient-Derived Xenografts (2017) (0)
Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types (2016) (0)
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer (2021) (0)
Abstract IA22: Targeting mTOR for breast cancer therapy (2015) (0)
Abstract B104: Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer withPIK3CA/AKT1mutations (2019) (0)
Differential Regulation Of Tumor Suppressor PDCD4 Expression By Rapamycin (2011) (0)
Development of a public knowledgebase to facilitate decision support for clinical cancer genomics reporting and clinical trial enrollment. (2015) (0)
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors (2017) (0)
Abstract CT278: ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers (2023) (0)
Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007) (2023) (0)
Title: Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA Short Title: Cell-free DNA in hepatocellular carcinoma Authors: (2019) (0)
Abstract CT032: Activity and safety of alectinib for ALK-altered solid tumors from MyPathway (2022) (0)
Next-generation sequencing: How close are we to clinical application? (2014) (0)
779P Validation of prognostic scores in patients with metastatic bladder carcinoma (mBC) enrolled in early phase clinical trials (2020) (0)
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies (2015) (0)
Abstract A202: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform. (2013) (0)
Eukaryotic Initiation Factor 4E (eIF4E) can be effectively downregulated using small interfering RNA (siRNA), inhibiting growth in breast cancer cells (2007) (0)
Everolimus inAdvancedPancreaticNeuroendocrineTumors: The Clinical Experience (2013) (0)
Identifying functional loss of ATM gene in patients with advanced cancer. (2020) (0)
112. ClinGen Somatic Cancer Variant Interpretation (CVI) committee and the Somatic Cancer expert panel process (2022) (0)
Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. (2022) (0)
mTOR modulates cellular fat metabolism by regulating stearoyl-CoA desaturase 1 transcription. (2009) (0)
Abstract 2618: Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in cholangiocarcinoma with FGFR fusions/rearrangements (2022) (0)
Genomic profiling and precision medicine in 3,745 patients with advanced cancer. (2014) (0)
Non-V600 BRAF mutations in advanced malignancies: Prevalence and survival impact. (2018) (0)
Erratum: Expression of sigma 1 receptor in human breast cancer (Breast Cancer Research and Treatment (2004) 87 (205-214)) (2005) (0)
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers (2018) (0)
ClinSeK: a targeted variant characterization framework for clinical sequencing (2015) (0)
Racial differences in the use of contralateral prophylactic mastectomy among women undergoing BRCA1/BRCA2 genetic testing. (2009) (0)
P2-15-01: Surgical Patterns of Care after Magnetic Resonance Imaging in the Academic Setting in Patients with Operable Breast Cancer Treated with Neoadjuvant Systemic Therapy: A Secondary Analysis of TBCRC 017. (2011) (0)
Abstract 4276: T200: a high depth targeted exome sequencing platform to identify actionable alterations in FFPE solid tumor samples (2014) (0)
Abstract A39: Patient-derived xenografts to test emerging therapies for triple negative breast cancer (2016) (0)
66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors (2022) (0)
Abstract 1791: Epigenetically upregulating TROP2 enhances therapeutic efficacy of TROP2 ADC sacitizumab govitecan (2022) (0)
488 Development of a publicly accessible knowledgebase to facilitate decision support for clinical cancer genomics reporting (2014) (0)
PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. (2014) (0)
Clinical Data do not Support the Hypothesis that Irradiation Promotes Biologically Aggressive Local Recurrences through Stromal Activation (2009) (0)
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. (2012) (0)
Abstract CT061: Binimetinib in patients with tumors withNRASmutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A (2020) (0)
Relationship between differences in RNA or protein expression and the effects of race/ethnicity on breast cancer outcomes. (2011) (0)
BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla). (2014) (0)
Pathologic Complete Response to Neoadjuvant Chemotherapy Plus Trastuzumab Predicts for Improved Survival in Women With HER2-positive Breast Cancer (2012) (0)
Abstract 2448: mTOR inhibitor MLN0128 Has antitumor efficacy in cell lines with intrinsic and acquired rapamycin resistancein vitroandin vivo. (2013) (0)
Reply to M.P. Decatris et al. (2016) (0)
Reply to J.J. Tao et al. (2018) (0)
Abstract LB-310: Single cell genome sequencing reveals clonal stability and diversity in breast cancer (2014) (0)
Abstract 5237: B-Raf V600E harboring non-melanoma cancers treated with Vemurafenib monotherapy and in combination with Everolimus/Sorafenib/Crizotinib/Paclitaxel+ Carboplatin: A pooled analysis of five phase 1/2 studies (2022) (0)
Abstract 493: Quantity of KRAS mutations in cell-free DNA is associated with survival of patients with advanced cancers (2016) (0)
Abstract CT058: TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors (2023) (0)
Abstract C080: The combination of MEK and MDM2 inhibitors demonstrates promising antitumor efficacy in MAPK altered patient-derived thyroid and colorectal cancer models (2019) (0)
1–30 Defining Negative Margins in DCIS Patients Treated With Breast Conservation Therapy: The University of Chicago Experience (2006) (0)
Variety of clinical trial enrollment by actionable tumor suppressor genotype. (2020) (0)
Abstract P3-01-09: A phase I clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer (2016) (0)
Abstract PR13: Investigating the importance of low allele frequency mutations for cancer patient management (2015) (0)
Abstract 3997: Outcomes of geriatric sarcoma patients enrolled in phase 1 clinical trials (2019) (0)
Effects of ethnicity on genotype-phenotype correlations in individuals with a BRCA1 or BRCA2 mutation. (2010) (0)
Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of cancer therapy. (2020) (0)
Abstract A19: A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC) (2020) (0)
Abstract 6181: Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials (2023) (0)
Clinical and molecular characterization of early-onset colorectal cancer patients with inflammatory bowel disease. (2018) (0)
Abstract P4-10-14: Risk of Ipsilateral Breast Events in Patients with Ductal Carcinoma In Situ after Local Excision (2010) (0)
Clinical Data Do Not Support the Hypothesis That Irradiation Promotes Biologically Aggressive Local Recurrences through Stromal Activation. (2009) (0)
Abstract 5687: Detection and monitoring of IDH mutations in unamplified plasma cell-free DNA in patients with advanced cancers treated with IDH inhibitors (2017) (0)
Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations (2015) (0)
Abstract LB-176: Identification of mutations in histone modification genes in Hodgkin lymphoma (2015) (0)
Abstract 3172: Evaluation of cytotoxic T cell infiltration and clinical benefit from PD-L1 checkpoint inhibition among PIK3CA mutant microsatellite stable (MSS) metastatic adenocarcinoma patients (2020) (0)
Abstract P1-03-01: Generation of a NovelIn VivoModel of Patient-Derived Chemoresistant Breast Cancers: (2010) (0)
Outcomes of sentinel lymph node-positive breast cancer patients treated with mastectomy without axillary therapy. (2013) (0)
Postmastectomy Radiation Therapy After Positive Sentinel Lymph Node Biopsy and Completion Axillary Lymph Node Dissection (2014) (0)
1 Category : Rapid Impact 1 Title : Molecular profiling of metastatic bladder cancer early-phase clinical trial participants 2 predicts patient outcomes 3 (2020) (0)
Abstract P6-18-13: Identification of optimal combination therapy partners for PI3K/Akt/mTOR pathway inhibitor in triple negative breast cancer (2019) (0)
2–27 Outcome After Invasive Recurrence in Patients With Ductal Carcinoma In Situ of the Breast (2005) (0)
Clinical factors that affect breast cancer risk reduction decisions in high risk women tested for the BRCA1/2 genetic mutation. (2006) (0)
Abstract 4424: Analysis of 1115 patients tested for MET amplification and therapy response in the MD Anderson phase I clinic (2014) (0)
Abstract 1588: Discordance of HER2 expression and/or amplification on repeat testing (2022) (0)
Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors. (2022) (0)
Abstract 2710: The MD Anderson patient-derived xenograft series for modeling precision oncology in biliary tract cancers (2021) (0)
8 Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist (2020) (0)
Multiple independent methods fail to confirm MET amplification rate reported in literature for metastatic colorectal cancer (mCRC). (2015) (0)
Abstract 738: Utility of Assessing HER2 RNA expression for precision medicine (2020) (0)
485P Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials (2022) (0)
Abstract P6-04-12: STAT3 as a therapeutic target in estrogen receptor positive breast cancer patients refractory to CDK4/6 inhibition (2020) (0)
Epithelial-mesenchymal transition confers resistance to rapamycin (2011) (0)
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. (2023) (0)
Global evaluation of minimal residual disease in primary breast cancer patients (2008) (0)
Abstract P4-06-04: Triple negative breast cancer patient-derived xenografts: Molecular characteristics and sensitivity to emerging therapies (2017) (0)
Abstract P047: A phase 1/2 trial of CBX-12, an alphalexTM peptide drug conjugate, in patients with advanced or metastatic refractory solid tumors (2021) (0)
Phase I trial of paclitaxel, bevacizumab, and temsirolimus in advanced solid malignancies. (2016) (0)
Abstract P3-04-01: Molecular determinants of post-mastectomy breast cancer recurrence (2018) (0)
CCR Perspectives in Drug Approval (2013) (0)
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial (2022) (0)
Breast cancer multifocality-multicentricity and survival outcomes. (2012) (0)
Predictors of Nonsentinel Node Metastasis in Patients With Breast Cancer After Sentinel Node Metastasis (2005) (0)
The rate of novel actionable mutations in standard of care NGS panel testing in gastrointestinal malignancies. (2018) (0)
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. (2021) (0)
Abstract 5152: Mutation-agnostic detection of colorectal cancer-specific cell-free DNA using targeted methylation sequencing (2022) (0)
Integrated transcriptomic–genomic tool Texomer profiles cancer tissues (2019) (0)
Comprehensive genomic profiling reveals recurrent XPO1 mutations and other alterations in archival samples of patients with Hodgkin lymphoma (2016) (0)
Abstract 3275: Bromodomain and extraterminal (BET) protein inhibition sensitize BRAFV600E colorectal cancer to standard targeted therapies (2022) (0)
Abstract CT094: Phase I study of fibroblast growth factor receptor 2 antibody-drug conjugate (FGFR2-ADC) BAY 1187982 in patients with advanced cancer (2017) (0)
Abstract B07: TAK228 enhances antitumor activity of eribulin in triple-negative breast cancer (2020) (0)
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience (2022) (0)
A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis (2022) (0)
Abstract 392: Patient-specific, tiered, variant-level actionability correlates with functional effect in growth survival assay (2021) (0)
Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER+) breast cancer or advanced solid tumors. (2022) (0)
Contents Vol. 91, 2016 (2016) (0)
Abstract 162: Biomarker identification of residual triple negative breast cancer (TNBC) after standard neoadjuvant chemotherapy (NCT) (2012) (0)
Locoregional Recurrence Rates in Young Women With Breast Cancer by Treatment Approach (2007) (0)
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101) (2023) (0)
Postmastectomy Breast Reconstruction Using a Microvascular Breast-Sharing Technique (2006) (0)
Abstract 1768: Anti-tumor activity and biomarker analysis for datopotamab deruxtecan in breast cancer PDX models (2022) (0)
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience (2017) (0)
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation (2019) (0)
Abstract CT146: A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC) (2016) (0)
Intraoperative Margin Analysis in Breast-Conserving Surgery (2008) (0)
c-Met abnormatities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors. (2014) (0)
Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin. (2014) (0)
Informatics Infrastructure for Routine Personalized Medicine (2013) (0)
Cancer-related internet use in patients with advanced cancer in a phase I clinical trials clinic (2016) (0)
Intramammary lymph node metastases are an independent predictor in breast cancer outcomes. (2004) (0)
Out of pocket costs and financial toxicity experienced by patients in early phase clinical trials. (2019) (0)
Learning Patient Representations from Electronic Health Records across Diverse Data Types (2020) (0)
Prospecting whole cancer genomes (2020) (0)
Erratum: Genotype in BRCA-associated Breast Cancers. (Breast Journal (2013) 19 (87-91)) (2013) (0)
Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (2022) (0)
125PTargeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes (2017) (0)
Abstract P6-05-06: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status (2023) (0)
1 mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV 39 H 1 in BRCA-proficient triple-negative breast cancer (2015) (0)
Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis. (2023) (0)
Abstract 5802: Efficacy of PI3Kβ inhibitor AZD8186 in PTEN-deficient triple-negative breast cancer (2018) (0)
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. (2023) (0)
Abstract 4275: Identifying cancer driver mutations in clinical sequencing data (2014) (0)
Chemotherapy: Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site‐ and Sequence‐Specific Drug Release (Adv. Funct. Mater. 30/2014) (2014) (0)
Phase I, ﬁ rst-in-human study of futibatinib, a highly selective, irreversible FGFR1 e 4 inhibitor in patients with advanced solid tumors (0)
Reply: Strategy for Nonresponder Breast Cancer Patients to Neoadjuvant Treatment (2011) (0)
Abstract 1202: A repository of PDX histology images for exploring spatial heterogeneity and cancer dynamics (2022) (0)
Abstract P6-20-12: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells (2019) (0)
Translational Research in Space Exploration (2007) (0)
Abstract P6-14-10: Treatment of Breast Cancer Using Multistage Delivery of PI3K/mTOR Inhibitors (2010) (0)
Abstract P1-13-04: Efficacy of adjuvant 5-Fluorouracil in residual HER2-negative breast cancer following neoadjuvant chemotherapy (2019) (0)
Survival and signals of response in advanced sarcoma patients enrolled on phase 1 trials in the era of precision oncology and novel immunotherapies. (2019) (0)
Incorporating Precision Medicine into Phase I Clinical Trials (2020) (0)
Abstract P1-07-09: Estrogen receptor positivity: 10% or 1%? (2012) (0)
Abstract 2273: Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response (2016) (0)
Abstract 2499: Clinical and immunopathological effects following Image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers (2015) (0)
Intratumor immunotherapy utilizing real time radiological image guidance: Early experience from a tertiary cancer center. (2020) (0)
CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors (2022) (0)
Abstract OT2-03-03: Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (2016) (0)
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory (2019) (0)
Radiation Dose Escalation for Locoregionally Recurrent Breast Cancer (2009) (0)
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts (2022) (0)
Mutation position in BRCA-associated breast cancers. (2010) (0)
Pembrolizumab in advanced rare cancers (2019) (0)
Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations (2015) (0)
1–28 Molecular Clonality Relationships in Initial Carcinomas, Ipsilateral Breast Failures, and Distant Metastases in Patients Treated with Breast-conserving Therapy: Evidence Suggesting That Some Distant Metastases Are Derived From Ipsilateral Breast Failures and That Metastases Can Metastasize (2006) (0)
Abstract 135: Targeted therapy of hormone receptor-positive breast cancer harboringPIK3CAandAKT1genetic aberrations (2017) (0)
Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer. (2018) (0)
Rate of incidental germline findings detected by tumor-normal matched sequencing in cancer types lacking hereditary cancer testing guidelines. (2021) (0)
Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells (2019) (0)
Imaging , Diagnosis , Prognosis Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer (2011) (0)
Abstract 3291: Development of a novel prognostic scoring system for patient selection in immune checkpoint inhibitor phase 1 clinical trials (2017) (0)
Significant Improvement in Regional Recurrence in Young Patients with Breast Cancer Treated with Comprehensive Nodal Irradiation (2008) (0)
Abstract PO-208: Patient-reported out-of-pocket costs and financial toxicity during early- phase oncology clinical trials (2020) (0)
Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance. (2017) (0)
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer (2012) (0)
Abstract 2371: Multi-cell phylogenetic inference of copy number evolution in breast cancer (2016) (0)
Abstract 3017: Advancing PDX research through model, data, and bioinformatics with the PDXNet Portal (2021) (0)
Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. (2023) (0)
Abstract C198: BRAF mutation testing of archival tumor samples with a novel, rapid, fully-automated molecular diagnostics prototype platform. (2013) (0)
274 Characteristics and clinical outcomes of patients with recurrent microsatellite stable endometrial cancer undergoing early phase immunotherapy clinical trials (2020) (0)
Abstract 3431: Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC (2023) (0)
Predictors of recurrence among patients with breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant systemic chemotherapy. (2011) (0)
Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer (2022) (0)
Abstract 2128: Genomic alterations in DNA mismatch repair (dMMR) (2023) (0)
Acknowledgement to reviewers (2015) (0)
425 Evaluation of drug reactions to anti-neoplastic agents in Phase I clinical trials (2014) (0)
Clinical utilization of precision oncology decision support for genomically-informed cancer therapy. (2016) (0)
72MO Selinexor in combination with standard chemotherapy in patients with advanced solid tumours: Results of an open label, single-center, multi-arm phase Ib study (2020) (0)
Abstract A023: Influence of pre-diagnosis obesity and post-diagnosis aspirin use on survival from stage IV colorectal cancer (2022) (0)
Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study. (2021) (0)
Mammalian target of rapamycin (mTOR) and eIF4E regulate stearoyl CoA desaturase 1 expression through modulation of SREBP1 in breast cancer cell lines (2009) (0)
Phase I study of and bevacizumab in patients with advanced cancers. (2018) (0)
Biology of Human Tumors In fl uence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer (2014) (0)
Abstract OT3-2-05: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (2015) (0)
Initial biopsy procedure for breast cancer diagnosis influences number of surgical procedures and cost of care. (2006) (0)
QS111. Correlation of COX-2 Expression With Triple Receptor Negative Status in Operable Human Breast Cancer (2008) (0)
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer (2023) (0)
Next-generation sequencing in carcinoma of unknown primary (CUP) and novel combinatorial strategies in a heterogeneous mutational landscape: Implications for personalized medicine. (2014) (0)
Abstract B191: Target-matched therapies in patients with advanced cervical cancers harboring PIK3CA mutations and/or PTEN loss. (2013) (0)
Abstract 2407: MultiplexKRASG12/G13 mutation testing of 16ng of unamplified cell-free DNA from plasma of patients with advanced cancers using Droplet Digital PCR (2015) (0)
Abstract 4742:APCWT/RASWT/BRAFWTtumors represent an under recognized poor prognostic group of right sided colorectal cancer (2017) (0)
Out-of-pocket costs and financial toxicity experienced by patients in early-phase clinical trials. (2019) (0)
Abstract P2-12-13: Knowledge and Information seeking about personalized breast cancer therapy (2015) (0)
554P Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study (2020) (0)
Abstract P058: Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterations (2021) (0)
Abstract C44: Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced cancers (2015) (0)
Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer (2022) (0)
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology. (2021) (0)
Erratum: Earlier age of onset of BRCA mutation‐related cancers in subsequent generations (2012) (0)
Abstract 564:BRAFV600mutation in circulating tumor DNA can predict outcomes in early-stage melanoma (2021) (0)
1871 Inhibition of mTOR in combination with chemotherapy and angiogenic blockade shows activity in metaplastic breast cancer, an aggressive, chemo-refractory subtype of triple-negative breast cancer (TNBC) (2015) (0)
Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations. (2017) (0)
Molecular determinants of post-mastectomy breast cancer recurrence (2018) (0)
Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer (2020) (0)
Abstract P6-13-14: Temporospatial delivery of chemotherapeutics from nanoparticles for synergy enhancement (2016) (0)
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study (2021) (0)
Identification of actionable genomic alterations utilizing cfDNA. (2018) (0)
Chemotherapeutic synergy enhancement through micellar nanotherapeutics (2010) (0)
Neratinib plus trastuzumab plus fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT 'basket' trial (2020) (0)
Abstract 1186: Patient-derived breast cancer xenografts demonstrate molecular evolution in the phosphatidylinositol 3-kinase pathway upon engraftment (2014) (0)
Abstract 3011: Phase I study of TT-00420, a multiple kinase inhibitor, in patients with triple negative breast cancers and other advanced solid tumors (2020) (0)
A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE). (2019) (0)
2022-RA-262-ESGO Predictors of oncologic outcome in recurrent cervical cancer patients receiving phase 1 cancer therapy (2022) (0)
Abstract 5607: BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers (2014) (0)
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer (2017) (0)
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response (2015) (0)
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations (2022) (0)
The impact of IMC nodal drainage on primary breast cancer outcome (2008) (0)
Abstract C50: Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer (2015) (0)
Efficacy of Pembrolizumab in Patients with Advanced Rare Cancers (2019) (0)
Effect of Trastuzumab on Locoregional Recurrence in HER2-Positive Breast Cancer According to ER/PR Status (2011) (0)
1085P Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors (2021) (0)
Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center. (2015) (0)
Abstract P6-20-11: The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models (2019) (0)
Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations. (2017) (0)
381 Role of CT scans of abdomen and pelvis in management of patients with immunotherapy-induced colitis (2020) (0)
Abstract 961: HER2-low expression in patients with advanced or metastatic solid tumors (2023) (0)
Abstract P1-19-18: Everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic cancer: Evaluating synergy and overcoming resistance (2020) (0)

This paper list is powered by the following services:

Funda Meric–bernstam's Academic­Influence.com Rankings

Funda Meric–bernstam's Degrees

Why Is Funda Meric–bernstam Influential?

Funda Meric–bernstam's Published Works

Published Works

Funda Meric–bernstam's AcademicInfluence.com Rankings